Teva Pharmaceutical Industries: Number of Employees 2012-2026 | TEVA
Interactive chart of Teva Pharmaceutical Industries (TEVA) annual worldwide employee count from 2012 to 2026.
- Teva Pharmaceutical Industries total number of employees in 2025 was 33,950, a 7.82% decline from 2024.
- Teva Pharmaceutical Industries total number of employees in 2024 was 36,830, a 2.7% decline from 2023.
- Teva Pharmaceutical Industries total number of employees in 2023 was 37,851, a 2.78% increase from 2022.
- Teva Pharmaceutical Industries total number of employees in 2022 was 36,826, a 1.89% decline from 2021.
| Teva Pharmaceutical Industries Annual Employee Count | |
|---|---|
| 2025 | 33,950 |
| 2024 | 36,830 |
| 2023 | 37,851 |
| 2022 | 36,826 |
| 2021 | 37,537 |
| 2020 | 40,216 |
| 2019 | 40,039 |
| 2018 | 42,535 |
| 2017 | 51,792 |
| 2016 | 56,960 |
| 2015 | 42,888 |
| 2014 | 43,000 |
| 2013 | 45,000 |
| 2012 | 45,948 |
| 2011 | 45,754 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $35.437B | $17.258B |
| Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |